ClinicalTrials.gg
CompletedNCT00746967Updated Feb 1, 2021

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

A Phase 2 interventional study of sildenafil in Sexual Dysfunctions, Psychological and Sexual Arousal Disorder, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 82 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
267
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Sexual Dysfunctions, Psychological with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Sexual Dysfunctions, Psychological · United States.

Enrollment
26th of 59
267 · median 196
Started
2003
with 2 others
Phase 2
13 of 62
1 open now
Registered
19th of 62
by date

Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, this one is the 26th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2003, is one of 13 in phase 2, and was the 19th registered.

Sexual Dysfunctions, Psychological

138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.

Browse Sexual Dysfunctions, Psychological studies →

Open to participants now

3 of the 62 studies in Sexual Dysfunctions, Psychological with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Sexual Dysfunctions, Psychological with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and toleration of oral sildenafil administered as required by women with Female Sexual Arousal Disorder (FSAD) who successfully complete one of the following Pfizer-sponsored, 12-week, double-blinded clinical trials: A1481082 or A1481123. Addition of this 52-week open-label extension will increase the total duration of sildenafil exposure to 64 weeks. Sustained efficacy will also be evaluated after 3 and 6 months of open-label therapy.

03

Conditions studied

  • Sexual Dysfunctions, Psychological
  • Sexual Arousal Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Included were subjects who completed Pfizer study A1481082 or A1481123 without a major protocol violation and with all treatment-related adverse events resolved prior to crossover into the open-label study.
  • For subjects receiving hormone replacement therapy and/or selective serotonin reuptake inhibitor treatment, dosage of these must be stable at the start of this extension study and remain stable throughout.
  • Subjects should continue to maintain a stable sexual relationship throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Excluded were subjects who experienced either treatment-related serious adverse events or significant treatment-related laboratory abnormalities in the previous study, and subjects who misused study medication and/or failed to adequately account for study medication in the previous study, or who were non-compliant with visits.
  • Also excluded were subjects who were currently prescribed and/or taking nitrates or nitric oxide donors in any form (oral, sublingual, buccal, transdermal, inhalational or aerosols).
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
267 participants (actual)

Study arms

  • Other
    Arm 1

    Drug: sildenafil

Interventions

  • sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks

06

What researchers measure

Primary outcomes

  1. Safety/toleration of oral sildenafil.

    Time frame: Continuous

Secondary outcomes

  1. The score for each of the individual questions 3,5 and 9 on the SQoL-F

    Time frame: Week 14 and Week 26

  2. The total satisfaction score on the Inventory of Treatment Satisfaction (ITS-modified EDITS)

    Time frame: Week 14 and Week 26

  3. The score for each of the individual questions 3,5,6 and 7 on the ITS-modified EDITS

    Time frame: Week 14 and Week 26

  4. The Arousal-lubrication Domain from the SFQ. The score for this domain is the sum of scores from Questions 11 and 12 from the SFQ

    Time frame: Week 14 and Week 26

  5. The Arousal-sensation Domain from the SFQ. The score for this domain is sum of scores from Questions 7,8,9 and 10 from the SFQ.

    Time frame: Week 14 and Week 26

  6. The total Quality of Life score on the Sexual Quality of Life (SQoL-F)

    Time frame: Week 14 and Week 26

  7. The Desire domain from the SFQ. Specifically, the sum of scores from questions 1,2,3,4,15 and 28 (frequency of pleasurable thoughts, wanted to be touched, wanted sex, initiated sex, had sex with penetration, looked forward to sex, respectively).

    Time frame: Week 14 and Week 26

  8. Question 16 from the SFQ at Weeks 14 and 26 (enjoyment of penetration and intercourse).

    Time frame: Week 14 and Week 26

  9. The Orgasm domain from the SFQ. The score for this domain is the sum of scores from questions 24,25 and 26 (orgasm frequency, level of pleasure and ease in achieving, respectively).

    Time frame: Week 14 and Week 26

  10. The individual questions of the Orgasm domain.

    Time frame: Week 14 and Week 26

  11. SFQ Question 27 (confidence as sexual partner).

    Time frame: Week 14 and Week 26

  12. SFQ Question 29 (disappointment with response).

    Time frame: Week 14 and Week 26

  13. Global Efficacy Question (SFQ Question 34, satisfaction with whole of sexual life)

    Time frame: Week 14 and Week 26

07

Study locations

82 sites
  • Pfizer Investigational Site
    Huntsville, Alabama 35801, United States
  • Pfizer Investigational Site
    Anchorage, Alaska 99502, United States
  • Pfizer Investigational Site
    Anchorage, Alaska 99508, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85712, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85719, United States
  • Pfizer Investigational Site
    Jonesboro, Arkansas 72401, United States
  • Pfizer Investigational Site
    Albany, California 94706, United States
  • Pfizer Investigational Site
    Berkeley, California 94705, United States
  • Pfizer Investigational Site
    Beverly Hills, California 90210, United States
  • Pfizer Investigational Site
    Beverly Hills, California 90212, United States
  • Pfizer Investigational Site
    Burbank, California 91506, United States
  • Pfizer Investigational Site
    Fair Oaks, California 95628, United States
  • Pfizer Investigational Site
    Hermosa Beach, California 90254, United States
  • Pfizer Investigational Site
    Oakland, California 94612, United States
  • Pfizer Investigational Site
    San Diego, California 92103, United States
  • Pfizer Investigational Site
    San Diego, California 92108, United States
  • Pfizer Investigational Site
    Santa Monica, California 90404, United States
  • Pfizer Investigational Site
    Torrance, California 90505, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80012, United States
  • Pfizer Investigational Site
    Hamden, Connecticut 06518, United States
  • Pfizer Investigational Site
    New London, Connecticut 06320, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06708, United States
  • Pfizer Investigational Site
    Aventura, Florida 33180, United States
  • Pfizer Investigational Site
    Brooksville, Florida 34614, United States
  • Pfizer Investigational Site
    Jensen Beach, Florida 34957, United States
  • Pfizer Investigational Site
    Miami, Florida 33186, United States
  • Pfizer Investigational Site
    New Port Richey, Florida 34652, United States
  • Pfizer Investigational Site
    Palm Harbor, Florida 34683, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida 33028, United States
  • Pfizer Investigational Site
    Plantation, Florida 33324, United States
  • Pfizer Investigational Site
    Saint Petersburg, Florida 33710, United States
  • Pfizer Investigational Site
    Stuart, Florida 34994, United States
  • Pfizer Investigational Site
    Stuart, Florida 34996, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33409, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30309, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30342, United States
  • Pfizer Investigational Site
    Marietta, Georgia 30060, United States
  • Pfizer Investigational Site
    Savannah, Georgia 31405, United States
  • Pfizer Investigational Site
    Boise, Idaho 83702, United States
  • Pfizer Investigational Site
    Boise, Idaho 83712, United States
  • Pfizer Investigational Site
    Evansville, Indiana 47714, United States
  • Pfizer Investigational Site
    Fort Wayne, Indiana 46825, United States
  • Pfizer Investigational Site
    Newburgh, Indiana 47630, United States
  • Pfizer Investigational Site
    Leawood, Kansas 66211, United States
  • Pfizer Investigational Site
    Crestview Hills, Kentucky 41017, United States
  • Pfizer Investigational Site
    Florence, Kentucky 41042, United States
  • Pfizer Investigational Site
    Metairie, Louisiana 70002, United States
  • Pfizer Investigational Site
    Greenbelt, Maryland 20770, United States
  • Pfizer Investigational Site
    Kalamazoo, Michigan 49009, United States
  • Pfizer Investigational Site
    Southfield, Michigan 48034, United States
  • Pfizer Investigational Site
    Creve Coeur, Missouri 63141, United States
  • Pfizer Investigational Site
    Henderson, Nevada 89014, United States
  • Pfizer Investigational Site
    North Las Vegas, Nevada 89030, United States
  • Pfizer Investigational Site
    New Brunswick, New Jersey 08903, United States
  • Pfizer Investigational Site
    New York, New York 10021, United States
  • Pfizer Investigational Site
    Poughkeepsie, New York 12601, United States
  • Pfizer Investigational Site
    Rochester, New York 14609, United States
  • Pfizer Investigational Site
    White Plains, New York 10603, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Beachwood, Ohio 44122-5402, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45267-0559, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19106, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19148, United States
  • Pfizer Investigational Site
    Reading, Pennsylvania 19606, United States
  • Pfizer Investigational Site
    Reading, Pennsylvania 19607-1649, United States
  • Pfizer Investigational Site
    Temple, Pennsylvania 19560, United States
  • Pfizer Investigational Site
    West Reading, Pennsylvania 19611-1499, United States
  • Pfizer Investigational Site
    Providence, Rhode Island 02904, United States
  • Pfizer Investigational Site
    Anderson, South Carolina 29621, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38119, United States
  • Pfizer Investigational Site
    Austin, Texas 78705, United States
  • Pfizer Investigational Site
    Austin, Texas 78758, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
  • Pfizer Investigational Site
    Houston, Texas 77024, United States
  • Pfizer Investigational Site
    Sandy, Utah 84070, United States
  • Pfizer Investigational Site
    Charlottesville, Virginia 22903, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23294, United States
  • Pfizer Investigational Site
    Renton, Washington 98055, United States
  • Pfizer Investigational Site
    Seattle, Washington 98105, United States
  • Pfizer Investigational Site
    Seattle, Washington 98115, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • Pfizer Investigational Site
    Cheyenne, Wyoming 82001, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2008
First posted
Sep 4, 2008
Start
Jan 2003
CompletionActual
Feb 2004
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00746967
Responsible party
Sponsor
First posted
Sep 4, 2008
Start date
Jan 2003
Completion
Feb 2004
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion